A split-face study assessing the clinical benefit, tolerability and subject satisfaction of a dermocosmetics cream containing sphingobioma and neurosensine in subjects with rosacea associated with erythema and sensitive skin

E. Berardesca, C. Cartigliani, M. Niore, A. Bonfigli, D. Kerob, J. Tan

INTRODUCTION & OBJECTIVES

Rosacea is a chronic inflammatory skin condition associated with an altered skin barrier and microbiome, inflammation and vasodilation.¹ Persistent erythema is a common primary feature, and can be associated with flushing, papules, as well as sensitive skin symptoms including tightness, stinging, burning and pain.^2,3 A specific dermocosmetic (DC) cream containing acetyl dipeptide-1 cetyl ester, a soothing compound (Neurosensine) that acts on skin sensitivity by decreasing erythema, irritation, and shea butter to moisturise the skin barrier has been developed for these patients.⁴ Moreover, DC cream contains an extract of a flagellated bacterial strain of Sphingomonas xenophaga isolated from the endogenous flora component of La Roche Posay Thermal Spring Water. It restores the skin barrier, decreases inflammation and redness and inhibits the activity of pre-Kallikrein.

This study assessed the benefit and local tolerance of DC cream in patients with rosacea associated with erythema and sensitive skin.